MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

748.88M

Vuru Grade

31.00/100

Current Price

$11.00
-0.77 (-6.54%)

Stability Price

$1.47
Overvalued by 86.63%

Company Metrics

  • P/E 13.83
  • P/S 9.06
  • P/B 2.04
  • EPS -1.19
  • Cash ROIC -5.97%
  • Cash Ratio 8.05
  • Dividend 0 / 0%
  • Avg. Vol. 731,747.00
  • Shares 51.66M
  • Market Cap. 748.88M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Inc. (MNTA) Drops 6.2% on February 08
Equities.com - 13 hours ago
Momenta Pharmaceuticals Inc. (MNTA) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 6.2% to $11.04, a loss of $-0.73 per share.
Analyst Coverage Updates - Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Risers & Fallers - Feb 4, 2016
Recently stock market analysts have updated their consensus ratings on shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Analysts Set Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Target Price at $25.20
EMQ - Jan 19, 2016
Momenta Pharmaceuticals logo Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) have earned an average recommendation of “Buy” from the thirteen analysts that are currently covering the company, Market Beat Ratings reports.
Stocks in Focus: Anadarko Petroleum Corporation (NYSE:APC), Twenty-First ... - Benchmark Monitor
Momenta Pharmaceuticals, Inc. – Pipeline Review, Market Share, Stragegy, Size ...
Medgadget.com (blog) - Jan 28, 2016
MRS2 “Momenta Pharmaceuticals, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of Momenta Pharmaceuticals, Inc. scenario. Report includes top line data relating on Momenta Pharmaceuticals, Inc. Global clinical trials scenario.
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today
Motley Fool - Jun 1, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib ... - GlobeNewswire (press release)
Momenta Pharmaceuticals, Inc. (MNTA) Upgraded to Buy at Zacks Investment Research
EMQ - Jan 16, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, MarketBeat Ratings reports.
Zacks Investment Research Upgrades Momenta Pharmaceuticals, Inc. (MNTA) to Buy - Zolmax
Momenta Pharmaceuticals Inc. (MNTA) Drops 5.83% on January 13
Equities.com - Jan 14, 2016
Momenta Pharmaceuticals Inc. (MNTA) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 5.83% to $13.01, a loss of $-0.805 per share.
Momenta Pharmaceuticals to Webcast Presentation at the 34th Annual J. P ...
GlobeNewswire (press release) - Jan 5, 2016
CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President ...
Investors Tracking Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s
Vanguard Tribune - Feb 6, 2016
Investors are following Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s stock movement, which recorded the first trade at 12.33 and was hovering around 11.77 lately.
Momenta Pharmaceuticals Appoints Matthew P. Ottmer as Chief Operating Officer
GlobeNewswire (press release) - Dec 7, 2015
CAMBRIDGE, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Matt Ottmer ...
Momenta Phama (MNTA) Names New COO - StreetInsider.com